Inhibitory activities of baicalin against renin and angiotensin-converting enzyme

References

• Black P, Wrapson C. (2001). ACE inhibitors for hypertension. N Z Med J, 114, 20–21.
   PubMedGoogle Scholar
• Blatt E, Chatelier RC, Sawyer WH. (1986). Effects of quenching mechanism and type of quencher association on Stern-Volmer plots in compartmentalized systems. Biophys J, 50, 349–356.
   PubMedGoogle Scholar
• Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Bühler FR. (1972). Essential hypertension: Renin and aldosterone, heart attack and stroke. N Engl J Med, 286, 441–449.
   PubMed Web of Science ®Google Scholar
• China Pharmacopoeia Committee, Pharmacopoeia of the People’s Republic of China, the first division of 2010 ed., China Chemical Industry Press, Beijing, 1999, p. 282–283.
   Google Scholar
• Cumin F, Evin G, Fehrentz JA, Seyer R, Castro B, Menard J, Corvol P. (1985). Inhibition of human renin by synthetic peptides derived from its prosegment. J Biol Chem, 260, 9154–9157.
   PubMed Web of Science ®Google Scholar
• Cushman DW, Cheung HS. (1971). Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol, 20, 1637–1648.
   PubMed Web of Science ®Google Scholar
• Epps DE, Raub TJ, Caiolfa V, Chiari A, Zamai M. (1999). Determination of the affinity of drugs toward serum albumin by measurement of the quenching of the intrinsic tryptophan fluorescence of the protein. J Pharm Pharmacol, 51, 41–48.
   PubMed Web of Science ®Google Scholar
• Graves JW. (2002). Additional side effects of ACE inhibitors. Am Fam Physician, 66, 2048.
   PubMedGoogle Scholar
• Huang Y, Tsang SY, Yao X, Chen ZY. (2005). Biological properties of baicalein in cardiovascular system. Curr Drug Targets Cardiovasc Haematol Disord, 5, 177–184.
   PubMedGoogle Scholar
• Israili ZH, Hall WD. (1992). Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med, 117, 234–242.
   PubMed Web of Science ®Google Scholar
• Lin CC, Shieh DE. (1996). The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am J Chin Med, 24, 31–36.
   PubMed Web of Science ®Google Scholar
• Lynch KR, Peach MJ. (1991). Molecular biology of angiotensinogen. Hypertension, 17, 263–269.
   PubMed Web of Science ®Google Scholar
• Maibaum J, Feldman DL. (2003). Renin inhibitors as novel treatments for cardiovascular disease. Expert Opin Ther Pat,13, 589–603.
   Web of Science ®Google Scholar
• Morice AH, Brown MJ, Higenbottam T. (1989). Cough associated with angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol, 13 Suppl 3, S59–S62.
   Google Scholar
• Peach MJ. (1977). Renin-angiotensin system: Biochemistry and mechanisms of action. Physiol Rev, 57, 313–370.
   PubMed Web of Science ®Google Scholar
• Quay SC, Heropoulos A, Commes K, Dzau VJ. (1985). Probing the renin active site by collisional quenching of endogenous fluorescence. J Biol Chem, 260, 15055–15058.
   PubMedGoogle Scholar
• Remková A, Remko M. (2010). The role of renin-angiotensin system in prothrombotic state in essential hypertension. Physiol Res, 59, 13–23.
   PubMedGoogle Scholar
• Sarver RW, Peevers J, Cody WL, Ciske FL, Dyer J, Emerson SD, Hagadorn JC, Holsworth DD, Jalaie M, Kaufman M, Mastronardi M, McConnell P, Powell NA, Quin J 3rd, Van Huis CA, Zhang E, Mochalkin I. (2007). Binding thermodynamics of substituted diaminopyrimidine renin inhibitors. Anal Biochem, 360, 30–40.
   PubMed Web of Science ®Google Scholar
• Shah RV, Desai AS, Givertz MM. (2010). The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: A systematic review and meta-analysis. J Card Fail, 16, 260–267.
   PubMed Web of Science ®Google Scholar
• Sibanda BL, Blundell T, Hobart PM, Fogliano M, Bindra JS, Dominy BW, Chirgwin JM. (1984). Computer graphics modelling of human renin. Specificity, catalytic activity and intron-exon junctions. FEBS Lett, 174, 102–111.
   PubMed Web of Science ®Google Scholar
• Stanton A. (2003). Potential of renin inhibition in cardiovascular disease. J Renin Angiotensin Aldosterone Syst, 4, 6–10.
   PubMed Web of Science ®Google Scholar
• Stanton A, Jensen C, Nussberger J, O’Brien E. (2003). Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension, 42, 1137–1143.
   PubMed Web of Science ®Google Scholar
• Takizawa H, DelliPizzi AM, Nasjletti A. (1998). Prostaglandin I2 contributes to the vasodepressor effect of baicalein in hypertensive rats. Hypertension, 31, 866–871.
   PubMed Web of Science ®Google Scholar
• Wang GT, Chung CC, Holzman TF, Krafft GA. (1993). A continuous fluorescence assay of renin activity. Anal Biochem, 210, 351–359.
   PubMed Web of Science ®Google Scholar
• Wood JM, Maibaum J, Rahuel J, Grütter MG, Cohen NC, Rasetti V, Rüger H, Göschke R, Stutz S, Fuhrer W, Schilling W, Rigollier P, Yamaguchi Y, Cumin F, Baum HP, Schnell CR, Herold P, Mah R, Jensen C, O’Brien E, Stanton A, Bedigian MP. (2003). Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun, 308, 698–705.
   PubMed Web of Science ®Google Scholar
• Yuan L, Wu J, Aluko RE, Ye X. (2006). Kinetics of renin inhibition by sodium houttuyfonate analogs. Biosci Biotechnol Biochem, 70, 2275–2280.
   PubMed Web of Science ®Google Scholar
• Yuan L, Wu J, Aluko RE. (2007). Size of the aliphatic chain of sodium houttuyfonate analogs determines their affinity for renin and angiotensin I converting enzyme. Int J Biol Macromol, 41, 274–280.
   PubMedGoogle Scholar
• Zaman MA, Oparil S, Calhoun DA. (2002). Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov, 1, 621–636.
   PubMed Web of Science ®Google Scholar